TY  - EJOUR
DO  - 10.5402/2011/549870
AB  - Few biopharmaceutical preparations developed from biologicals are available for tissue regeneration and scar management. When developing biological treatments with cellular therapy, selection of cell types and establishment of consistent cell banks are crucial steps in whole-cell bioprocessing.  Various cell types have been used in treatment of wounds to reduce scar to date including autolog and allogenic skin cells, platelets, placenta and amniotic extracts.  Experience with fetal cells show that they may provide an interesting cell choice due to facility of out-scaling and known properties for wound healing without scar. Differential gene profiling has helped to point to potential indicators of repair which include cell adhesion, extracellular matrix, cytokines, growth factors and development.  Safety has been evidenced in Phase I & II clinical fetal cell use for burn and wound treatments with different cell delivery systems. Overall fetal cells present technical and therapeutic advantages compared to other cell types for effective cell-based therapy for wound and scar management. 
T1  - Biologicals and fetal cell therapy for wound healing and scar management
DA  - 2011
AU  - Hirt-Burri, Nathalie
AU  - Ramelet, Albert-Adrien
AU  - Raffoul, Wassim
AU  - De Buys Roessingh, Anthony
AU  - Scaletta, Corinne
AU  - Pioletti, Dominique P.
AU  - Laurent-Applegate, Lee Ann
JF  - ISRN Dermatology
SP  - 1-16
VL  - Article ID 549870
EP  - 1-16
ID  - 164267
KW  - wound healing
KW  - scars
KW  - chronic ulcers
KW  - cell therapy
UR  - http://infoscience.epfl.ch/record/164267/files/ISRN%28Nath%29.pdf
ER  -